JAMP OLMESARTAN 20 MG — DIN 02461641
OLMESARTAN MEDOXOMIL : 20 MG · JAMP PHARMA CORPORATION · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is JAMP OLMESARTAN?
JAMP OLMESARTAN 20 MG contains OLMESARTAN MEDOXOMIL : 20 MG. It is listed in the Health Canada Drug Product Database under DIN 02461641, held by JAMP PHARMA CORPORATION, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 28-Oct-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is JAMP OLMESARTAN used for?
Treatment of mild to moderate essential hypertension. May be used alone or in combination with thiazide diuretics.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Olmesartan Medoxomil cost around the world?
Olmesartan Medoxomil is listed on 3 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Belgium publishes a public; Morocco publishes a PPV (public price). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 62 | 166 | AUD███.██ |
| Belgium | public | 83 | 83 | EUR███.██ |
| Morocco | PPV (public price) | 1 | 3 | MAD███.██ |
252 pack listings across 146 brand entries and 3 price bases, refreshed 08 Sep 2026. Ranges span every Olmesartan Medoxomil pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Olmesartan Medoxomil in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
18 holders have a Canadian DIN containing Olmesartan Medoxomil, across 42 DINs, of which 22 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| AURO PHARMA INC | 3 | 2 | AURO-OLMESARTAN | Sourceable in Canada |
| ORGANON CANADA INC. | 3 | 2 | OLMETEC | Sourceable in Canada |
| PRO DOC LIMITEE | 3 | 2 | OLMESARTAN | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 3 | 2 | SANDOZ OLMESARTAN | Sourceable in Canada |
| SANIS HEALTH INC | 3 | 2 | OLMESARTAN | Sourceable in Canada |
| ACCORD HEALTHCARE INC | 2 | 2 | ACH-OLMESARTAN | Sourceable in Canada |
| GLENMARK PHARMACEUTICALS CANADA INC. | 2 | 2 | GLN-OLMESARTAN | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 2 | 2 | JAMP OLMESARTAN | Sourceable in Canada |
| NORA PHARMA INC | 2 | 2 | NRA-OLMESARTAN | Sourceable in Canada |
| PHARMASCIENCE INC | 2 | 2 | PMS-OLMESARTAN | Sourceable in Canada |
| TEVA CANADA LIMITED | 2 | 2 | TEVA-OLMESARTAN | Sourceable in Canada |
| APOTEX INC | 3 | 0 | APO-OLMESARTAN | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 20 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Bottles of 90 tablets and blister packs of 30 (3 x 10) tablets. |
| Storage | Not explicitly detailed in provided text (section 11 header present but content truncated). Typical range is 15-30°C. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Olmesartan Medoxomil |
|---|---|
| ATC code | C09CA08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02461641 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2461641 |
| Brand name | JAMP OLMESARTAN |
| Generic / active ingredient | OLMESARTAN MEDOXOMIL : 20 MG |
| Market authorization holder | JAMP PHARMA CORPORATION |
| Health Canada schedule | Prescription |
| ATC code | C09CA08 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C09CA |
| Current status | MARKETED |
| Status date | 28-Oct-2021 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Adults: 20 mg once daily starting dose, may increase to 40 mg. Pediatrics (6-16 years): 10 mg (<35 kg) or 20 mg (≥35 kg) once daily. May be taken with or without food.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity; concomitant use with aliskiren in patients with diabetes or renal impairment; pregnancy; breastfeeding.
Warnings and precautions
Fetal toxicity; hypotension in volume/salt-depleted patients; sprue-like enteropathy (severe chronic diarrhea); hyperkalemia; impaired renal function.
Is Olmesartan Medoxomil in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Anticipated — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
22 of 42 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-OLMESARTAN | 20 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | 02456311 |
| ACH-OLMESARTAN | 40 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | 02456338 |
| AURO-OLMESARTAN | 40 MG | TABLET | AURO PHARMA INC | MARKETED | 02443872 |
| AURO-OLMESARTAN | 20 MG | TABLET | AURO PHARMA INC | MARKETED | 02443864 |
| GLN-OLMESARTAN | 20 MG | TABLET | GLENMARK PHARMACEUTICALS CANADA INC. | MARKETED | 02469812 |
| GLN-OLMESARTAN | 40 MG | TABLET | GLENMARK PHARMACEUTICALS CANADA INC. | MARKETED | 02469820 |
| JAMP OLMESARTAN | 40 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02461668 |
| NRA-OLMESARTAN | 40 MG | TABLET | NORA PHARMA INC | MARKETED | 02499266 |
| NRA-OLMESARTAN | 20 MG | TABLET | NORA PHARMA INC | MARKETED | 02499258 |
| OLMESARTAN | 40 MG | TABLET | SANIS HEALTH INC | MARKETED | 02481065 |
2 · Same class — other molecules in ATC C09CA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Candesartan | ACCEL-CANDESARTAN · ACH-CANDESARTAN · ACT CANDESARTAN · AG-CANDESARTAN · +24 more | 126 | 51 | Yes |
| Irbesartan | ACT IRBESARTAN · AG-IRBESARTAN · APO-IRBESARTAN · AURO-IRBESARTAN · +23 more | 103 | 38 | Yes |
| Valsartan | ACT VALSARTAN · APO-VALSARTAN · AURO-VALSARTAN · AVA-VALSARTAN · +17 more | 85 | 31 | Yes |
| Losartan | ACT LOSARTAN · AG-LOSARTAN · APO-LOSARTAN · AURO-LOSARTAN · +18 more | 81 | 27 | Yes |
| Telmisartan | ACH-TELMISARTAN · ACT TELMISARTAN · AG-TELMISARTAN · ALEMBIC-TELMISARTAN · +20 more | 52 | 26 | Yes |
| Olmesartan Medoxomil | ACH-OLMESARTAN · AG-OLMESARTAN · APO-OLMESARTAN · AURO-OLMESARTAN · +12 more | 42 | 22 | Yes |
| Azilsartan Medoxomil | AURO-AZILSARTAN MEDOXOMIL · EDARBI | 4 | 4 | Yes |
| Eprosartan | TEVETEN · TEVETEN TABLETS 300 MG | 3 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is JAMP OLMESARTAN called?
The same molecule, Olmesartan Medoxomil, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Olmetec | Latin | Australia, Morocco |
| APX-Olmesartan/HCTZ | Latin | Australia |
| OLMEKAR | Latin | Australia |
| Olmesartan HCT Viatris | Latin | Australia |
| Olmesartan/Amlodipine Sandoz | Latin | Australia |
| Olmesartan/HCT Sandoz | Latin | Australia |
| Olmetec Plus | Latin | Australia |
| APO-Olmesartan | Latin | Australia |
| APX-Olmesartan | Latin | Australia |
| Blooms The Chemist Olmesartan | Latin | Australia |
| OLMERTAN | Latin | Australia |
| Olmesartan - MYL | Latin | Australia |
| Olmesartan Sandoz | Latin | Australia |
| OLMESARTAN-WGR | Latin | Australia |
| Olsetan | Latin | Australia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.